Literature DB >> 16893496

CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system.

Keqiang Chen1, Jian Huang, Wanghua Gong, Lingzhi Zhang, Peichu Yu, Ji Ming Wang.   

Abstract

CD40 and its cognate ligand (CD40L) are a pair of regulators of pro-inflammatory and immune responses. In the central nervous system (CNS), CD40 is expressed on a variety of cells, including vascular endothelial cells, smooth muscle cells, astrocytes and microglia (the brain macrophages, being the most sensitive cell type to respond to CD40 ligand). Interaction between CD40 on microglia and CD40L presented by infiltrating T lymphocytes and other resident CNS cells triggers a series of intracellular signaling events that promote the production of a wide array of cytokines, chemokines and neurotoxins. Thus, both molecules serve as amplifiers of pro-inflammatory and immune responses in the CNS and constitute important molecular targets for therapeutic intervention of diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893496

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  34 in total

1.  Combination of EPA with Carotenoids and Polyphenol Synergistically Attenuated the Transformation of Microglia to M1 Phenotype Via Inhibition of NF-κB.

Authors:  Nurit Hadad; Rachel Levy
Journal:  Neuromolecular Med       Date:  2017-08-04       Impact factor: 3.843

2.  Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by Δ(9)-tetrahydrocannabinol in human CD4(+) T cells.

Authors:  Thitirat Ngaotepprutaram; Barbara L F Kaplan; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2013-08-30       Impact factor: 4.219

Review 3.  The multifaceted profile of activated microglia.

Authors:  Marina A Lynch
Journal:  Mol Neurobiol       Date:  2009-07-23       Impact factor: 5.590

4.  Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice.

Authors:  William V Nikolic; Huayan Hou; Terrence Town; Yuyan Zhu; Brian Giunta; Cyndy D Sanberg; Jin Zeng; Deyan Luo; Jared Ehrhart; Takashi Mori; Paul R Sanberg; Jun Tan
Journal:  Stem Cells Dev       Date:  2008-06       Impact factor: 3.272

Review 5.  Impact of the CD40-CD40L dyad in Alzheimer's disease.

Authors:  Brian Giunta; Kavon Rezai-Zadeh; Jun Tan
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

6.  CD40-CD40 Ligand Pathway is a Major Component of Acute Neuroinflammation and Contributes to Long-term Cognitive Dysfunction after Sepsis.

Authors:  Monique Michels; Lucinéia Gainski Danieslki; Andriele Vieira; Drielly Florentino; Dhébora Dall'Igna; Letícia Galant; Beatriz Sonai; Francieli Vuolo; Franciele Mina; Bruna Pescador; Diogo Dominguini; Tatiana Barichello; João Quevedo; Felipe Dal-Pizzol; Fabrícia Petronilho
Journal:  Mol Med       Date:  2015-03-26       Impact factor: 6.354

7.  Use of laser microdissection in the investigation of facial motoneuron and neuropil molecular phenotypes after peripheral axotomy.

Authors:  Nichole A Mesnard; Thomas D Alexander; Virginia M Sanders; Kathryn J Jones
Journal:  Exp Neurol       Date:  2010-06-04       Impact factor: 5.330

Review 8.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

9.  Activation of CD40 by soluble recombinant human CD40 ligand inhibits human glioma cells proliferation via nuclear factor-κB signaling pathway.

Authors:  Yong Zhang; Tao Huang; Yi Hu; Yu Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-10-18

10.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.